NEW YORK, July 23 – Oxford Glycosciences and Hybrigenics have entered into a collaboration to study OGS’ protein drug targets, the companies said Monday.
The arrangement calls for Paris-based Hybrigenics to identify how a selected number of protein targets associated with cancer and neurological disorders interact with Hybrigenic’s library of proteins. The results will help OGS prioritize its existing drug targets and could potentially uncover new proteins with potential as drug targets, the companies said.
Hybrigenics and OGS of London will share the data generated from the collaboration equally, and OGS has an option to exclusively commercialize any products that result. OGS will fund Hybrigenics’ research, but other financial details were not disclosed.
Hybrigenics has developed several techniques for studying how proteins interact based on yeast two-hybrid and other cellular screening technologies. The company assembles this interaction information in the form of maps, and sells maps of protein interactions in Helicobacter pylori, Hepatitis C virus, and Saccharomyces cerevisiae .
OGS signed a similar drug development deal with NeoGenesis, a chemical genomics company based in Cambridge, Mass. Under that deal, NeoGenesis will attempt to identify small molecule compounds from its library that bind with OGS protein targets.
In May, Hybrigenics, said it had opened a joint research facility with Institut Curie in Paris, where researchers will map cellular protein interactions in Drosophila melangaster and human cells to validate critical protein pathways involved in cancer.